C. Prost‐Squarcioni

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

P. Joly, Maud Maho‐Vaillant, C. Prost‐Squarcioni et al. · The Lancet · 2017 · 596 citations

Medicine, Internal Medicine, Pharmacotherapy +9

Diagnosis and management of pemphigus: Recommendations of an international panel of experts

Dédée F. Murrell, S.M. Peña, P. Joly et al. · Journal of the American Academy of Dermatology · 2018 · 373 citations · Full text

Veterinary Medicine, Pathobiology, Pathology +6

ADAMTSL2 mutations in geleophysic dysplasia demonstrate a role for ADAMTS-like proteins in TGF-β bioavailability regulation

Carine Le Goff, Fanny Morice‐Picard, Nathalie Dagoneau et al. · Nature Genetics · 2008 · 245 citations · Full text

Life Sciences, Genetics, Molecular Biology +9

Rituximab for Patients With Refractory Mucous Membrane Pemphigoid

C. Le Roux‐Villet, C. Prost‐Squarcioni, M. Alexandre et al. · Archives of Dermatology · 2011 · 146 citations · Full text

Medicine, Immunology, Pharmacotherapy +9

Prevalence and Clinical Significance of Anti–Laminin 332 Autoantibodies Detected by a Novel Enzyme-Linked Immunosorbent Assay in Mucous Membrane Pemphigoid

Philippe Bernard, Frank Antonicelli, Christophe Bédane et al. · JAMA Dermatology · 2013 · 101 citations

Life Sciences, Immunology, Pathology +14